Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
53,514,204
-
Total 13F shares
-
15,926,513
-
Share change
-
-262,411
-
Total reported value
-
$42,841,966
-
Price per share
-
$2.69
-
Number of holders
-
28
-
Value change
-
-$711,172
-
Number of buys
-
8
-
Number of sells
-
7
Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) as of Q4 2022
As of 31 Dec 2022,
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,926,513 shares.
The largest 10 holders included
Bain Capital Life Sciences Investors, LLC, Atlas Venture Life Science Advisors, LLC, Octagon Capital Advisors LP, FMR LLC, RiverVest Venture Management LLC, Rock Springs Capital Management LP, VANGUARD GROUP INC, Artal Group S.A., HARVARD MANAGEMENT CO INC, and Trustees of Columbia University in the City of New York.
This page lists
28
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.